Xiaoying Zhou

Dr. Xiaoying Zhou


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2015 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
XZXiaoying Zhou
Xiaoying Zhou
WJWujuan Jin
Wujuan Jin
HJHongyan Jia
Hongyan Jia
JYJin Yan
Jin Yan
GZGuoxin Zhang
Guoxin Zhang
Increasing evidence showed that miRNAs serve as modulators of human cancer, either as oncogene or tumor suppressors. Cisplatin resistance is the most common cause of chemotherapy failure in gastric cancer (GC). However, the roles of miRNAs in cisplatin resistance of GC remain largely unknown. The aim of the study was to identify a novel miRNA/gene pathway that regulates the sensitivity of GC cells to cisplatin. In this study, we chose miR-223 by qRT-PCR analysis, the most significantly up-regulated miRNA in GC, to investigate its formation of DDP-resistant phenotype of GC cells and possible molecular mechanisms. We found that miR-223 was most significantly up-regulated miRNA in DDP-resistant GC cells compared with parental GC cells. Besides, its expression was also significantly up-regulated in GC tissues. FBXW7 was identified as the direct and functional target gene of miR-223. Overexpression of FBXW7 could mimic the effect of miR-223 down-regulation and silencing of FBXW7 could partially reverse the effect of miR-223 down-regulation on DDP resistance of DDP-resistant GC cells. Besides, miR-223 and FBXW7 could affect the G1/S transition of cell cycle by altering some certain cell cycle regulators. Furthermore, miR-223 was found to be significantly up-regulated in H. pylori infected tissues and cells, suggesting that H. pylori infection may lead to GC development and DDP resistance. Our findings revealed the roles of miR-223/FBXW7 signaling in the DDP resistance of GC cells and targeting it will be a potential strategic approach for reversing the DDP resistance in human GC.

19 February 2015 in Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
XZXiaoying Zhou
Xiaoying Zhou
WLWei Liu
Wei Liu
MGMin Gu
Min Gu
HZHongwen Zhou
Hongwen Zhou
GZGuoxin Zhang
Guoxin Zhang

11 February 2023 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
HCHan Chen
Han Chen
RORong Ou
Rong Ou
NTNana Tang
Nana Tang
WSWei Su
Wei Su
RYRuoyun Yang
Ruoyun Yang
XZXiaoying Zhou
Xiaoying Zhou
Background: Gut dysbacteriosis has been reported as one of the etiologies for irritable bowel syndrome (IBS). However, the association between gut microbiota and IBS is still inconclusive. Method: A paired-sample study was designed by retrieving original multicenter 16 s-rRNA data of IBS patients and healthy controls from the GMrepo database. The propensity score matching (PSM) algorithm was applied to reduce confounding bias. The differential analysis of microbiota composition was performed at different taxonomic levels. The co-occurrence network was established. Subgroup analysis was performed to identify specific microbial compositions in different IBS subtypes. Results: A total of 1522 amplicon samples were initially enrolled. After PSM, 708 individuals (354 IBS and 354 healthy controls) were eligible for further analysis. A total of 1,160 genera were identified. We identified significantly changed taxa in IBS groups (IBS-enriched: the families Enterobacteriaceae, Moraxellaceae and Sphingobacteriaceae; the genera Streptococcus, Bacillus, Enterocloster, Sphingobacterium, Holdemania and Acinetobacter. IBS-depleted: the phyla Firmicutes, Euryarchaeota, Cyanobacteria, Acidobacteria and Lentisphaerae; the families Bifidobacteriaceae, Ruminococcaceae, Methanobacteriaceae and the other 25 families; the genera Faecalibacterium, Bifidobacterium and other 68 genera). The co-occurrence network identified three hub genera and six hub species (including Faecalibacterium prausnitzii) that may be involved in IBS pathophysiology. Strong positive interactions were identified among the Bifidobacterium longum, Bifidobacterium breve and Bifidobacterium adolescentis in the Bifidobacterium community. Conclusion: This study provides quantitative analysis and visualization of the interaction between the gut microbiota and IBS. The identification of key species should be further validated to evaluate their causal relationships with the pathogenesis of IBS.

16 March 2015 in Gastroenterology Research and Practice
Verified
Journal Article
Open access
PDF file
LLLin Li
Lin Li
LLLingling Li
Lingling Li
XZXiaoying Zhou
Xiaoying Zhou
SXShuping Xiao
Shuping Xiao
HGHuiyuan Gu
Huiyuan Gu
GZGuoxin Zhang
Guoxin Zhang
Background. Several studies have shown a possible involvement ofHelicobacter pylori(H. pylori) infection in individuals with hyperemesis gravidarum (HG), but the relationship remains controversial. This meta-analysis was performed to validate and strengthen the association between HG andH. pyloriinfection.Methods. PubMed, Embase, and Web of Science databases up to March 20, 2014, were searched to select studies on the prevalence ofH. pyloriinfection between pregnant women with HG and the normal pregnant control subjects.Results. Of the HG cases, 1289 (69.6%) wereH. pylori-positive; however, 1045 (46.2%) wereH. pylori-positive in control group. Compared to the non-HG normal pregnant controls, infection rate ofH. pyloriwas significantly higher in pregnant women with HG (OR = 3.34, 95% CI: 2.32–4.81,P<0.001). Subgroup analysis indicated thatH. pyloriinfection was a risk factor of HG in Asia, Africa, and Oceania, especially in Africa (OR = 12.38, 95% CI: 7.12–21.54,P<0.001).Conclusions.H. pylorishould be considered one of the risk factors of HG, especially in the developing countries.H. pylorieradication could be considered to relieve the symptoms of HG in some intractable cases.

19 December 2023 in Aging
Verified
Journal Article
Open access
PDF file
HCHan Chen
Han Chen
XTXinyu Tang
Xinyu Tang
WSWei Su
Wei Su
SLShuo Li
Shuo Li
RYRuoyun Yang
Ruoyun Yang
XZXiaoying Zhou
Xiaoying Zhou
Background: Despite the widespread use of statins, newer lipid-lowering drugs have been emerging. It remains unclear how the long-term use of novel lipid-lowering drugs affects the occurrence of cancers and age-related diseases. Methods: A drug-target Mendelian randomization study was performed. Genetic variants of nine lipid-lowering drug-target genes (HMGCR, PCKS9, NPC1L1, LDLR, APOB, CETP, LPL, APOC3, and ANGPTL3) were extracted as exposures from the summary data of Global Lipids Genetics Consortium Genome-Wide Association Studies (GWAS). GWAS summary data of cancers and noncancerous diseases were used as outcomes. The inverse-variance weighted method was applied as the main statistical approach. Sensitivity tests were conducted to evaluate the robustness, pleiotropy, and heterogeneity of the results. Results: In addition to marked effects on decreased risks of atherosclerotic cardiovascular diseases, genetically proxied lipid-lowering variants of PCKS9, CETP, LPL, LDLR, and APOC3 were associated with longer human lifespans (q<0.05). Lipid-lowering variants of ANGPTL3 and LDLR were associated with reduced risks of colorectal cancer, and ANGPTL3 was also associated with lower risks of gastric cancer (q<0.05). Lipid-lowering LPL variants were associated with decreased risks of hypertension, type 2 diabetes, nonalcoholic fatty liver disease, and bladder cancer (q<0.05). Lipid-lowering variants of PCKS9 and HMGCR were associated with decreased risks of osteoporosis (q<0.05). Lipid-lowering APOB variants were associated with a decreased risk of thyroid cancer (q<0.05). Conclusions: Our study provides genetic evidence that newer nonstatin lipid-lowering agents have causal effects on decreased risks of several common cancers and cardiometabolic diseases. These data provide genetic insights into the potential benefits of newer nonstatin therapies.

1 November 2022 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
HCHan Chen
Han Chen
NTNana Tang
Nana Tang
QYQiang Ye
Qiang Ye
XYXin Yu
Xin Yu
RYRuoyun Yang
Ruoyun Yang
XZXiaoying Zhou
Xiaoying Zhou
Background: Although the gut microbiota may be involved in obesity onset and progression, the exact association of the gut microbiota in metabolically healthy obesity (MHO) remains largely unknown.Methods: An integrated paired-sample metagenomic analysis was conducted to investigate the gut microbial network and biomarkers of microbial species from the MHO and healthy non-obese subjects in the GMrepo database. Further explorations were performed in the MHO mice model using a multiomics analysis to detect changes in the composition and function of the intestinal microbiome and associated metabolites.Results: In the human study, 314 matched metagenomic data were qualified for the final analysis. We identified seven significantly changed species possibly involved in MHO pathogenesis (MHO-enriched: Bacteroides vulgatus, Megamonas sp; MHO-depleted: Butyrivibrio crossotus, Faecalibacterium prausnitzii, Bacteroides cellulosilyticus; Eubacterium siraeum; Bacteroides massiliensis). In the murine study, we found 79 significantly-changed species which may have possible associations with the MHO phenotype. The depletion of Bacteroides cellulosilyticus was commonly recognized in the human and murine MHO phenotype. Consistent with the metagenomic data, liquid chromatography-mass spectrometry (LC/MS) revealed significantly changed gut metabolites, which may promote MHO pathogenesis by altering the amino acids and lipid metabolic pathways. In the microbe-metabolites interaction analysis, we identified certain fatty acids (Dodecanedioic acid, Arachidic Acid, Mevalonic acid, etc.) that were significantly correlated with the MHO-enriched or depleted species.Conclusion: This study provides insights into identifying specific microbes and metabolites that may involve in the development of obesity without metabolic disorders. Future modalities for MHO intervention may be further validated by targeting these bacteria and metabolites.